
New Lung Cancer Drug Shows 70% Response Rate at ASCO 2026
A promising new lung cancer treatment called Pumitamig is giving hope to patients with advanced disease, showing a 70% response rate regardless of their PD-L1 status. The breakthrough was announced at the 2026 ASCO conference, one of the world's leading cancer research gatherings.
